Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

[Press release – not published yet] Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of monoclonal antibodies

13 Apr, 2021 | 05:26h | UTC

Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (Casirivimab with Imdevimab) – Regeneron

Commentaries: Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV – STAT AND Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81% – Endpoint News

 

Cohort study: SARS-CoV-2 infection rates of antibody-positive vs. antibody-negative health-care workers – previous infection was associated with 84% lower risk of (re)infection

12 Apr, 2021 | 01:30h | UTC

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) – The Lancet

Commentary: Correlates of protection from SARS-CoV-2 infection – The Lancet

 

Commentary on Twitter

 

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

13 Apr, 2021 | 05:23h | UTC

They Tested Negative for Covid. Still, They Have Long Covid Symptoms. – Kaiser Health News

 

Commentary on Twitter

 

Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients

12 Apr, 2021 | 01:23h | UTC

Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients – Critical Care

 

Commentary on Twitter

 

[Preprint] Pfizer vaccine less effective for SARS-CoV-2 variant B.1.351

12 Apr, 2021 | 01:26h | UTC

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals – medRxiv

Commentaries: South African variant may evade protection from Pfizer vaccine, Israeli study says – Reuters AND Israeli data shows South African variant able to ‘break through’ Pfizer vaccine – The Times of Israel

Related: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.

 

[Preprint] Efficacy and safety of CoronaVac in healthcare professionals in Brazil

12 Apr, 2021 | 01:17h | UTC

Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study – SSRN

 

Commentary on Twitter (thread – click for more)

 

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

12 Apr, 2021 | 01:20h | UTC

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine – TCTMD

Study 1: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination – New England Journal of Medicine

Study 2: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine

 

Japanese doctors perform world’s first living donor lung transplant to a Covid-19 patient

12 Apr, 2021 | 01:12h | UTC

Japanese doctors perform world’s first living donor lung transplant to a Covid-19 patient – CNN

 

EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine

12 Apr, 2021 | 01:18h | UTC

EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine – Health Policy Watch

See also: Johnson & Johnson’s COVID-19 vaccine under scrutiny at EMA after 4 ‘serious cases’ of unusual blood clots – Fierce Pharma AND J&J COVID-19 vaccine under EU review over blood clots, AstraZeneca probe grows – Reuters

 

Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil

12 Apr, 2021 | 01:14h | UTC

Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil – Science

Original study: [Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil (study and commentary on Twitter)

 

Comprehensive Review | Pneumonia

9 Apr, 2021 | 03:14h | UTC

Pneumonia – Nature Reviews Disease Primers (free for a limited period)

Try this link if the above is paywalled.

 

Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

12 Apr, 2021 | 01:24h | UTC

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil

9 Apr, 2021 | 03:36h | UTC

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?

9 Apr, 2021 | 03:28h | UTC

Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? – The Lancet Diabetes & Endocrinology

 

The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19

9 Apr, 2021 | 03:35h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 – NIH COVID-19 Treatment Guidelines

 

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

8 Apr, 2021 | 09:14h | UTC

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records – The Lancet Psychiatry

Commentaries: 1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds – STAT AND A longer look at COVID-19 and neuropsychiatric outcomes – The Lancet Psychiatry AND Largest study to date suggests link between COVID-19 infection and subsequent mental health and neurological conditions – The Lancet AND Covid-19: One in three has neurological or psychiatric condition diagnosed after covid infection, study finds – The BMJ AND One in three survivors of severe Covid diagnosed with mental health condition – The Guardian AND Covid-19 linked to depression and dementia, study suggests – BBC AND Expert reaction to observational study looking at neurological and psychiatric outcomes 6 months after COVID-19 – Science Media Centre AND 1 in 3 COVID Survivors Struggle With Mental Health Issues Months Later – HealthDay

 

Commentary on Twitter (thread – click for more)

 

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

8 Apr, 2021 | 09:12h | UTC

One in ten have long-term effects 8 months following mild COVID-19 – Karolinska Institutet

Original study: Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers – JAMA

 

Commentary on Twitter

 

Study: Outdoor transmission accounts for 0.1% of Covid-19 cases

8 Apr, 2021 | 09:11h | UTC

Outdoor transmission accounts for 0.1% of State’s Covid-19 cases – The Irish Times

Related: Systematic review: Outdoor transmission of SARS-CoV-2 and other respiratory viruses. “The odds of indoor transmission was very high compared to outdoors (18.7 times)”

 

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca

8 Apr, 2021 | 09:05h | UTC

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca – GOV.UK

Original report: MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots – Medicines and Healthcare products Regulatory Agency

Commentary: Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Commentary on Twitter

 

WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed

8 Apr, 2021 | 09:09h | UTC

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.

8 Apr, 2021 | 09:07h | UTC

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged <30 years to be offered an alternative COVID-19 vaccine, if available.”

8 Apr, 2021 | 09:02h | UTC

JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 – GOV.UK

Commentaries: Covid: Under-30s offered alternative to Oxford-AstraZeneca jab – BBC AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Video: Coronavirus Variants and Vaccines

8 Apr, 2021 | 09:00h | UTC

Coronavirus Variants and Vaccines – JAMA

 

Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials

8 Apr, 2021 | 08:59h | UTC

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California – JAMA Internal Medicine

Commentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly

 

Commentary on Twitter (thread – Click for more)

 

CDC Updated Guidance: “It is possible for people to be infected through contact with contaminated surfaces or objects, but the risk is generally considered to be low”

7 Apr, 2021 | 02:00h | UTC

Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments – Centers for Disease Control and Prevention

Related: Catching COVID from surfaces is very unlikely. So perhaps we can ease up on the disinfecting – The Conversation AND Coronavirus is in the air — there’s too much focus on surfaces – Nature AND COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.